Introduction {#s1}
============

Atopic dermatitis (AD) also known as atopic eczema, is an inflammatory, chronic and relapsing skin disorder [@pone.0093095-Hebert1] affecting 10% to 15% of the children worldwide [@pone.0093095-SchultzLarsen1]. The AD signs and symptoms are seen during first six months of life in 48% to 75% patients [@pone.0093095-Kay1], [@pone.0093095-WadondaKabondo1] and in 80%--85% of the patients at age of five years [@pone.0093095-Emerson1], [@pone.0093095-Hywel1]. There is no consistent overall trend for the incidence or prevalence of atopic eczema worldwide. However, a marked increase in lifetime prevalence of atopic eczema symptoms was seen in Africa, eastern Asia, Western Europe and parts of northern Europe [@pone.0093095-Deckers1].

AD is considered as the first symptom of the 'atopic march' [@pone.0093095-Xu1] and is characterized by itching, redness and skin creases [@pone.0093095-Hoare1]. It has a significant social, personal, emotional and economic impact on the life of patients and their family [@pone.0093095-Su1]. Pimecrolimus cream 1% is a promising FDA approved therapy for the clinical care of AD patients [@pone.0093095-Eichenfield1], [@pone.0093095-Gupta1]. Pimecrolimus cream 1% is an anti-inflammatory compound that blocks the T-cells proliferation and inhibits the production and release of numerous inflammatory mediators from mast cells [@pone.0093095-Gupta1], [@pone.0093095-GrahamBrown1]. It has a unique skin-selective pharmacologic profile [@pone.0093095-Stuetz1], [@pone.0093095-Grassberger1]. The various clinical trials in infants, children and adults have shown pimecrolimus to be effective in reducing incidence of major flares of the disease; thereby, improving the signs and symptoms of AD [@pone.0093095-Staab1]--[@pone.0093095-Wahn1]. The treatment of AD with pimecrolimus cream 1% is an important alternative to topical corticosteroids without the associated adverse events (AE) [@pone.0093095-Breuer1], [@pone.0093095-Ashcroft1].

AD starts in an early age (onset \<2 years of age) [@pone.0093095-Hoare1] and is a threat to the overall health and development of a child [@pone.0093095-Krakowski1]. The management of AD in children is a complex clinical challenge [@pone.0093095-Su1], [@pone.0093095-Akdis1]. Previous studies with pimecrolimus cream 1% have shown it to effective and well tolerated treatment for individuals of all age groups, at all levels of disease severity, irrespective of ethnic origin [@pone.0093095-Eichenfield1], [@pone.0093095-Wellington1], [@pone.0093095-Papp1]. It has also been observed to safe and effective on sensitive skin areas such as face and neck [@pone.0093095-Hebert1], [@pone.0093095-Wellington1]. The long term studies have shown that pimecrolimus 1% also improves the quality of life of patients [@pone.0093095-Ashcroft2].

Pimecrolimus was introduced into the market for the short-term treatment and long term control of AD. It had proved to be effective and safe and tried to replace weaker topical steroids in treatment of AD, however its place in the market is still unclear [@pone.0093095-GrahamBrown1], [@pone.0093095-Williams1].

Moreover, the clinical data from population of different age groups (infants, children or adults) produces heterogeneity in the results [@pone.0093095-Ashcroft1]. Little research has been focused on infants [@pone.0093095-Hoare1].The data on long term use of pimecrolimus for AD in children is lacking, as majority of the trials are conducted on population of small sample size. Hence, based on published randomized controlled trials (RCTs) and non-RCTs, we performed a meta-analysis to compare the efficacy and safety of pimecrolimus cream 1% with vehicle or tacrolimus in treating AD specifically in pediatric population.

Materials and Methods {#s2}
=====================

Search strategy {#s2a}
---------------

A bibliographic search of medical literature till July 2013 was performed using databases as PubMed, EMBASE and Web of Science. The search string ("Pimecrolimus" OR "SDZ ASM 981" OR "ELIDEL") AND ("atopic dermatitis" OR "dermatitis in children" OR "eczema") was used to search for relevant articles. The Cochrane library ([www.cochranelibrary.com](http://www.cochranelibrary.com)) was also searched. Reference lists of included studies and review articles were manually searched. Only original papers in English published in journals with a peer review process were included after reading the abstracts. The meta-analysis was limited to studies conducted in human.

### Inclusion and Exclusion Criteria {#s2a1}

Blinded, randomized or non-randomized, vehicle controlled or active comparator trials of pimecrolimus cream 1% reporting clinical relevant outcome measures like efficacy, safety or tolerability were selected. The study was eligible for inclusion if 1) the study was on pediatric patients (up to 17 years of age) with diagnosis of AD (mild, moderate or severe); 2) compared topical pimecrolimus 1% with vehicle (cream base, but not containing pimecrolimus) or an active comparator; 3) outcome measures was investigators\' global assessment (IGA), eczema area and severity index (EASI), time to first flare or pruritus assessment and; 4) had Jaded score ≥3 [@pone.0093095-Jadad1]. The study was excluded if 1) it was on adult population; 2) an open-labeled study; 3) non-comparative design; 4) either IGA or EASI scores missing; 5) contained previously published data.

The abstract of an article was reviewed if the title of the article and/or key words were relevant. The full text articles of all potentially relevant articles were read to consider the article for inclusion in the study. The reference lists of the included articles were cross checked to identify citations that could have been missed in the primary search steps. The articles reporting insufficient data, using non-standardized scoring systems, or lacking precise comparison methods were rejected. Two authors independently assessed the methodological quality of the included study and extracted the relevant data.

Intervention {#s2b}
------------

Pimecrolimus cream 1% or corresponding vehicle/active comparator was applied as a thin film to the affected areas twice daily.

Outcomes {#s2c}
--------

The primary outcome was IGA. EASI was reviewed in the articles wherever available. IGA scores utilize a six-point scale, ranging from 0 (clear) to 5 (very severe disease). IGA scores measure disease severity based on morphology, without referring back to the baseline state [@pone.0093095-Chen1]. EASI is a validated tool for objectively assessing the severity of eczema. It assesses erythema, infiltration/papulation, excoriation and lichenification separately on a 4-point-scale (0-3), in the head and neck region, trunk, upper limbs and lower limbs [@pone.0093095-Hanifin1]. The other efficacy outcome measures were puritus, caregiver assessments and flare free periods.

Adverse events (AEs) were assessed to compare safety. We also compared tolerability profile of pimercrolimus 1% and vehicle by performing a meta-analysis of total withdrawals from each group, discontinuations due to unsatisfactory therapeutic effects and total AEs.

Data extraction {#s2d}
---------------

The meta-analysis was reported as per the Quality of Reporting of Meta-analyses (QUOROM) statement [@pone.0093095-Moher1]. Two investigators independently assessed the quality of trials and any disagreement was resolved through discussion with the third author. The Jadad score was used to evaluate the quality analysis of methodology, including randomization, blinding and withdrawal from study. The Jadad scale scores from 1 to 5, where 1 or 2 indicates poor in quality and 3--5 indicates high quality [@pone.0093095-Jadad1].

Statistical analysis {#s2e}
--------------------

The statistical analysis was performed using software Review Manager 5.2. The output of the data is in the form of forest plot. The population varied in studies that we have selected for example the age of the subject varied from one study to another. Hence, effect size also varied, *i.e*, there was distribution of effect size, so we have used random effect model rather than fixed effect model. We have also investigated heterogeneity by splitting the studies into subgroups and looking at the forest plot and also calculated chi^2^ value. A p-value of \<0.1 was considered to be suggestive of statistical heterogeneity. The comparison of the effects between two groups is expressed in terms of odds ratio (OR) and its 95% confidence interval (95% CI). In order to avoid risk of bias, we have included only the blinded, controlled trials and excluded observational and follow up studies.

Results {#s3}
=======

Trial Flow {#s3a}
----------

A total of 81 relative studies published till July 2013 was obtained by electronic databases searches. Of these, 60 were excluded on the basis of title and abstract. The full texts of 21 articles were retrieved and read by two independent investigators. From these 21 articles identified, 14 articles were rejected because of data redundancy, the research goal/objective being different, extension study, an open labeled study, etc. Finally, seven articles (6 randomized and 1 non-randomized) met all entry criteria and were included in the meta-analysis. The trial flow is illustrated in [Figure 1](#pone-0093095-g001){ref-type="fig"}.

![Flowchart of trials.](pone.0093095.g001){#pone-0093095-g001}

Descriptions of studies {#s3b}
-----------------------

The characteristics of the included studies are given in [table 1](#pone-0093095-t001){ref-type="table"}. Of the seven studies, six studies were double-blinded and one was investigator blinded study. A total of 2,170 pediatric patients were enrolled in the included studies. Of these, three trials were conducted on infants (3 to 23 months, n = 638) [@pone.0093095-Ho1], [@pone.0093095-Kapp1], [@pone.0093095-Kaufmann1], one on infants and children (3 months to 11 years, n = 275) [@pone.0093095-Siegfried1] and three on children and adolescents (2 years to 17 years, n = 1,257) [@pone.0093095-Eichenfield2], [@pone.0093095-Wahn1]. The severity of participant\'s AD varied from mild to severe (IGA score = 2 to 4) in five trials [@pone.0093095-Eichenfield2], [@pone.0093095-Kapp1], [@pone.0093095-Wahn1], [@pone.0093095-Kaufmann1], [@pone.0093095-Siegfried1], mild to moderate (IGA score = 2 to 3) in one trial [@pone.0093095-Ho1] and moderate to severe (IGA = 3 to 4) in another trial [@pone.0093095-Kempers1].

10.1371/journal.pone.0093095.t001

###### Pimecrolimus (Study Characteristics).

![](pone.0093095.t001){#pone-0093095-t001-1}

  Study                                          Type                                n            Age                                                                          Center                                                                    Severity of AD                                 Intervention, control                                            Duration                          Outcome
  ------------------ ------------------------------------------------------------- ----- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------------------------------------------- ------------------------------------- ----------------------------
  Kapp, 2002          Double-blind, randomized vehicle-controlled parallel-group    251       3--23 months       Multicenter, 41 centers in 8 countries (Belgium, Canada, France, Germany, New Zealand, South Africa, Spain, and the United Kingdom)     Mild to severe                         1% pimecrolimus, Vehicle, twice daily                                     1 year                     IGA, EASI, Pruritus
  Siegfried, 2006     Double-blind, randomized Vehicle-controlled, parallel-group   275   3 months to 11 years                                              Multicenter, 35 centers in the United States                                                 Mild to severe                         1% pimecrolimus, vehicle, twice daily                                    6 months                    IGA, EASI, Pruritus
  Ho, 2003                         Double-blind, Vehicle-controlled                 186       3--23 months                                      25 centers in Australia, Brazil, Canada, Germany, South Africa, Spain                                   Mild to moderate                        1% pimecrolimus, vehicle, twice daily                       26 weeks **(Double Blind:6 weeks)**      IGA, EASI, Pruritus
  Kaufman, 2004               Double blind, randomizedVehicle-controlled            201       3--23 months                                                       Multicenter, 19 centers in Germany                                                      Mild to severe                         1% pimecrolimus, Vehicle, twice daily                       20 weeks **(Double Blind-4 weeks)**   IGA, EASI, Pruritus, sleep
  Wahn, 2002                 Double- Blind, randomized vehicle-controlled           713       2--17 years                          53 centers in 13 countries (9 in Europe, the United States, Canada, South Africa and Australia                        Mild to severe     1% pimecrolimus, Vehicle (Short term treatment: corticosteroids), twice daily                 1 year                          IGA, EASI
  Eichenfiel, 2002          Double-blinded, vehicle controlled, randomized          403       1--17 years                                                                    Multicenter                                                                 Mild to severe                              1% pimecrolimus,twice daily                                          6 weeks                         IGA, EASI
  Kemper, 2004                  Blinded randomizedParallel-group study              141       2--17 years                                                              Multicenter,19 centers                                                          Moderate to severe                            1% pimecrolimus, tacrolimus                            26weeks (**6 weeks blinded study)**              IGA

**Vehicle controlled trials.** Six trials (2,029 participants) compared 1% pimecrolimus cream applied twice daily against a vehicle control [@pone.0093095-Eichenfield2]--[@pone.0093095-Kapp1], [@pone.0093095-Wahn1], [@pone.0093095-Kaufmann1], [@pone.0093095-Siegfried1].

**Active controlled trials.** One trial (141 participants) compared 1% pimecrolimus cream against tacrolimus applied daily [@pone.0093095-Kempers1].

Efficacy {#s3c}
--------

The efficacy results of different comparisons have been summarized in different figures given below. The efficacy results include IGA, EASI score, flare free periods, improvement in puritus and caregiver assessments. The EASI score of the studies is presented in [table 2](#pone-0093095-t002){ref-type="table"}. Each individual study reported a significantly better reduction (p≤0.0001) in EASI score with pimecrolimus 1% as compared with vehicle.

10.1371/journal.pone.0093095.t002

###### Reduction in EASI scores.

![](pone.0093095.t002){#pone-0093095-t002-2}

  Study                Treatment   Vehicle/tacrolimus   Day   P value
  ------------------- ----------- -------------------- ----- ---------
  Siegfried, 2006        −34%              3%            8    \<0.001
  Ho, 2003              −81.69%           −25%          43    \<0.001
  Kaufman, 2004         −71.50            19.4          29    \<0.001
  Eichenfield, 2002      −45%              1%           43    ≤0.001

### Investigator-rated clinical response as clear or almost clear eczema (reduction in IGA) {#s3c1}

The IGA reduction was more with pimecrolimus 1% as compared with vehicle in individual studies. However, when we pooled the data of these individual studies, the reduction in IGA was in favor of vehicle as compared with pimecrolimus 1% at all time points ([Figure 2](#pone-0093095-g002){ref-type="fig"}).

![Analysis of reduction in IGA (Pimecrolimus vs vehicle).](pone.0093095.g002){#pone-0093095-g002}

A single trial that compared pimecrolimus 1% with tacrolimus 0.03% (125 participants) found no significant difference between the two groups (OR 0.67 95% CI 0.32--1.40) [@pone.0093095-Kempers1] ([Figure 3](#pone-0093095-g003){ref-type="fig"}).

![Analysis of reduction in IGA (pimecrolimus vs tacrolimus).](pone.0093095.g003){#pone-0093095-g003}

### No flare of eczema during treatment (Flare free periods) {#s3c2}

[Figure 4](#pone-0093095-g004){ref-type="fig"} shows the proportion and OR of participants who did not experience a flare of eczema. Kaufmann et al (195 participants) reported significantly more participants without flares in the pimecrolimus group compared against vehicle (OR 0.13, 95% CI 0.05--0.33) within eight days of the treatment [@pone.0093095-Kaufmann1]. However, at 6 months pimecrolimus did not seem to be beneficial (OR 1.69, 95% CI 1.45 to 1.96 in favor of vehicle) based on data from 3 trials involving 949 participants [@pone.0093095-Kapp1], [@pone.0093095-Wahn1], [@pone.0093095-Siegfried1].

![Analysis of flare free periods (pimecrolimus vs vehicle).](pone.0093095.g004){#pone-0093095-g004}

Mild or absent pruritus {#s3d}
-----------------------

The results of mild or absent pruritus at day 4 (OR 8.29, 95% CI 3.88--17.72), day 43 (OR 1.81 95% CI 1.13--2.89) and 1 week (OR 2.29, 95% CI 1.45 to 3.60) favored vehicle as compared against pimecrolimus. ([Figure 5](#pone-0093095-g005){ref-type="fig"}).When compared to tacrolimus, [@pone.0093095-Kempers1] no significant difference was observed in achieving mild or absent pruritus (OR 0.94, 95% CI 0.44--1.99) between the two treatment groups ([Figure 6](#pone-0093095-g006){ref-type="fig"}).

![Analysis of pruritus (pimecrolimus vs vehicle).](pone.0093095.g005){#pone-0093095-g005}

![Analysis of pruritus (pimecrolimus vs tacrolimus).](pone.0093095.g006){#pone-0093095-g006}

Caregiver\'s assessments {#s3e}
------------------------

According to care givers assessments, pimecrolimus did not rate better at showing improvement in overall disease (OR 3.30, 95% CI 2.03--5.35 favoring vehicle), day 29 (OR 14.14, 95% CI 6.87--29.13 favoring vehicle) and day 43 (OR 4.11, 95% CI 2.59--6.52 favoring vehicle) as compared with the vehicle group, based on pooled results ([Figure 7](#pone-0093095-g007){ref-type="fig"}).

![Analysis of care giver\'s assessment (pimecrolimus vs pruritus).](pone.0093095.g007){#pone-0093095-g007}

Adverse Events {#s3f}
--------------

The most common adverse events (AEs) were typical childhood infections and ailments. The pooled data for overall AEs showed that there was no significant difference between the total AEs in both groups (OR 1.19, 95% CI 0.85, 1.65) ([Figure 8](#pone-0093095-g008){ref-type="fig"}). However, overall study withdrawal (OR 0.44, 95% CI 0.35, 0.55) ([Figure 9](#pone-0093095-g009){ref-type="fig"}) and study withdrawal due to unsatisfactory therapeutic effect (OR 0.25, 95% CI 0.19, 0.34) were lesser in pimecrolimus group as compared with vehicle ([Figure 10](#pone-0093095-g010){ref-type="fig"}).

![Analysis of total Adverse events.](pone.0093095.g008){#pone-0093095-g008}

![Analysis of Study withdrawals.](pone.0093095.g009){#pone-0093095-g009}

![Analysis of Study withdrawals due to unsatisfactory therapeutic effects.](pone.0093095.g010){#pone-0093095-g010}

Discussion {#s4}
==========

The present meta-analysis was conducted to compare pimecrolimus 1% to vehicle/active comparator for the treatment of pediatrics AD. Seven double-blinded/investigator blinded, randomized/non-randomized, vehicle controlled/active comparator, multicentre studies were identified and the data was pooled and analyzed. We compared IGA, EASI score, pruritus assessments, care givers assessments and flare free periods of these studies. The safety of pimecrolimus cream 1% vs. vehicle and active comparator was also assessed in children. Overall, the results of this meta-analysis showed that pimecrolimus cream 1% was not significantly better to vehicle for AD in children.

AD is common disease of children with an overall prevalence of 10-15-%, [@pone.0093095-SchultzLarsen1], however, little data is available to assess its management in children. Pimecrolimus is a non-steroid inhibitor of inflammatory cytokines [@pone.0093095-Stuetz1] and is thought to be an important treatment for children as it does not induce skin atrophy [@pone.0093095-QueilleRoussel1]. Majority of the clinical trials with pimecrolimus have been carried out in adults and have shown promising results [@pone.0093095-Meurer1], [@pone.0093095-Gollnick1]--[@pone.0093095-Meurer2].

Evidence from short-term studies (4 weeks to 6 weeks) has shown that topical pimecrolimus 1% is safe and effective for the treatment of AD in infants [@pone.0093095-Ho1], [@pone.0093095-Kaufmann1], [@pone.0093095-Siegfried1] while the long term studies (6 to 12 months) have shown that pimecrolimus 1% significantly reduces the incidence of disease flares; thereby, controlling the signs and symptoms of AD [@pone.0093095-Kapp1], [@pone.0093095-Wahn1]. In the present meta-analysis, the three studies on very young population (3 to 23 months of age) have reported substantial clinical benefits in terms of safety and tolerability of pimecrolimus 1%. While the two studies on children and adolescents concluded that the use of pimecrolimus 1% to treat early signs and symptoms prevented the progression of major AD flares. However, the pooled results of these studies in meta-analysis did not yield promising results for pimecrolimus.

Ashcroft et al conducted a meta-analysis of 25 RCTs on 4186 patients using pimecrolimus 1% or tacrolimus 0.1% or 0.03% Both the drugs were significantly more effective than a vehicle control. However, the review was unable to show the long term safety of pimecrolimus or tacrolimus over corticosteroids. Also, due to absence of key comparisons with tacrolimus, the clinical importance for topical pimecrolimus was unclear [@pone.0093095-Ashcroft1]. In our meta-analysis, we were able to identify only one study that compared pimecrolimus 1% with tacrolimus 0.03% in pediatric patients. The study showed that though both had similar efficacy, but pimecrolimus achieved better tolerability than tacrolimus. However, it is difficult to comments on the efficacy of pimecrolimus as compared with tacrolimus through the data of a single study.

Chen et al in a meta-analysis of 20 trials involving 6288 infants and children with AD reported that both the treatments are safe and effective in pediatric patients with AD, with tacrolimus being superior to pimecrolimus. However, the authors have reported the possibility of evaluation bias of remissive effects in this systematic review [@pone.0093095-Chen1].

A Cochrane review from 31 clinical trials, involving 8019 participants observed that treatment of AD with pimecrolimus was effective when compared against vehicle. Again, this systematic review did not find evidence to support that pimecrolimus was better option to treat eczema than moderate or potent corticosteroids or tacrolimus. The pooled results reported no statistically significant difference between 1.0% pimecrolimus and 0.03% tacrolimus in achieving clear or almost clear of eczema and mild or absent pruritus following 1 week of the treatment [@pone.0093095-Ashcroft2].

We comprehensively searched for blinded, controlled trials from a wide range of databases in order to avoid the risk of publication bias, and used clinically relevant outcome measures. However, our meta-analysis has certain limitations. Due to a lack of relevant comparative data the clinical role of pimecrolimus is uncertain. Further, there is little evidence to support the use of pimecrolimus in infants. We compared rates of withdrawals, unsatisfactory therapeutic effects, and total AEs that were based on data pooled from trials of different durations. Moreover, long term safety (beyond 1 or 2 years) of use of pimecrolimus is lacking because it has been in use for less than a decade. Hence, long term trials are required in future to check its long term efficacy.

Though the present meta-analysis from large number of patients from more than 192 centers gives a doubtful view in the use of pimecrolimus 1% in infants and children, we suggest that pimecrolimus should be used with caution in this population taking in to consideration the clinical condition of these patients and available management strategies for AD in children.
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